Swedbank AB Boosts Stock Position in Stryker Corporation $SYK

Swedbank AB increased its stake in shares of Stryker Corporation (NYSE:SYK) by 6.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 129,027 shares of the medical technology company’s stock after purchasing an additional 7,934 shares during the quarter. Swedbank AB’s holdings in Stryker were worth $45,349,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Czech National Bank increased its position in Stryker by 3.9% during the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after purchasing an additional 3,366 shares in the last quarter. Davis R M Inc. increased its position in Stryker by 1.8% during the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after purchasing an additional 2,512 shares in the last quarter. Terra Alpha Investments LLC acquired a new stake in Stryker in the 3rd quarter worth about $1,216,000. Kepler Cheuvreux Suisse SA purchased a new stake in Stryker in the 3rd quarter valued at about $27,952,000. Finally, Daymark Wealth Partners LLC grew its holdings in Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after buying an additional 37,307 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on SYK shares. Truist Financial restated a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a report on Monday, May 4th. BTIG Research lowered their price target on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. UBS Group lowered their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Robert W. Baird set a $385.00 price target on Stryker in a report on Friday, May 1st. Finally, Piper Sandler restated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.60% of the stock is owned by corporate insiders.

Stryker Stock Performance

NYSE SYK opened at $316.39 on Monday. The firm has a market capitalization of $121.29 billion, a P/E ratio of 36.62, a P/E/G ratio of 1.99 and a beta of 0.80. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business’s 50-day simple moving average is $325.22 and its 200-day simple moving average is $349.76.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.